For first-degree relatives of patients with Crohn disease, increased antibody response is associated with subsequent risk for CD.
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the Phase III registration part ...
Immutep ( (IMMP)) has issued an announcement. On 22 December 2025, Immutep reported positive initial results from a placebo-controlled, double-blind first-in-human Phase I trial of IMP761, its ...
Given encouraging efficacy and safety, the trial will continue as planned and further updates are anticipated in 1H CY2026 including presentation of data at a major medical conference SYDNEY, ...
1 Collaborative Innovation Center for Translation Medical Testing and Application Technology, Department of Medical Technology, Zhangzhou Health Vocational College, Zhangzhou, Fujian, China 2 ...
The addition of neoadjuvant trastuzumab deruxtecan (T-DXd; Enhertu) significantly improved pathologic complete response (pCR) rates compared with anthracycline-containing chemotherapy in high-risk, ...
Specific antibody deficiency (SAD) is an immune system disorder. It occurs when you have normal levels of antibodies but an insufficient immune response to certain types of bacteria. Antibodies, also ...
In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents—antibody-drug conjugates (ADCs)—can dramatically improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results